drugset / Trial / NCT04016753

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

NCT04016753

Phase 1 Completed 32 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelDiagnostic

Summary

A comparative study of BMS-986256 with a combined oral contraceptive in healthy female participants to determine the effectiveness when taken together

Timeline

Start
2019-08-05
Primary completion
2020-02-21
Completion
2020-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Afimetoran Small molecule 30 mg
Subject Norethindrone Unknown 1.5 mg Oral
Subject ethinyl estradiol Small molecule 30 ug Oral

Indications

No indication recorded.